Update on the male hormonal contraceptive agents (Q35871918)

10 August 2017

1 reference

title

Update on the male hormonal contraceptive agents (English)

1 reference

10 August 2017

Melanie Walton

1

1 reference

PubMed ID

15330744

10 August 2017

Richard A Anderson

series ordinal

2

1 reference

PubMed ID

15330744

10 August 2017

language of work or name

English

0 references

publication date

1 September 2004

1 reference

Expert Opinion on Investigational Drugs

10 August 2017

1 reference

10 August 2017

13

1 reference

10 August 2017

9

1 reference

10 August 2017

1123-1133

1 reference

Clinical and Biochemical Parameters of Androgen Action in Normal Healthy CaucasianVersusChinese Subjects

10 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1123

CAG repeat length in the androgen receptor gene and gonadotrophin suppression influence the effectiveness of hormonal male contraception

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1123

Contraceptive efficacy of testosterone-induced azoospermia in normal men

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1123

Clinical trial with testosterone undecanoate for male fertility control

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1123

An oral regimen of cyproterone acetate and testosterone undecanoate for spermatogenic suppression in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1123

Sublingual administration of testosterone-hydroxypropyl-beta-cyclodextrin inclusion complex simulates episodic androgen release in hypogonadal men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1123

A comparison of a novel testosterone bioadhesive buccal system, striant, with a testosterone adhesive patch in hypogonadal males

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1123

A multicenter contraceptive efficacy study of injectable testosterone undecanoate in healthy Chinese men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1123

Investigation of a novel preparation of testosterone decanoate in men: pharmacokinetics and spermatogenic suppression with etonogestrel implants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1123

An analysis of testosterone implants for androgen replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1123

Androgens in men--uses and abuses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1123

Selective androgen receptor modulators (SARMs): a novel approach to androgen therapy for the new millennium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1123

Coregulator function: a key to understanding tissue specificity of selective receptor modulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1123

7 alpha-methyl-nortestosterone (MENT): the optimal androgen for male contraception

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1123

7alpha-methyl-19-nortestosterone, a synthetic androgen with high potency: structure-activity comparisons with other androgens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1123

Evidence for tissue selectivity of the synthetic androgen 7 alpha-methyl-19-nortestosterone in hypogonadal men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1123

Desogestrel plus testosterone effectively suppresses spermatogenesis but also causes modest weight gain and high-density lipoprotein suppression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1123

Oral desogestrel with testosterone pellets induces consistent suppression of spermatogenesis to azoospermia in both Caucasian and Chinese men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1123

Suppression of spermatogenesis by etonogestrel implants with depot testosterone: potential for long-acting male contraception

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1123

Levonorgestrel implants (Norplant II) for male contraception clinical trials: combination with transdermal and injectable testosterone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1123

Inhibition of spermatogenesis in men with monthly injections of medroxyprogesterone acetate and testosterone enanthate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1123

Attainment and maintenance of azoospermia with combined monthly injections of depot medroxyprogesterone acetate and testosterone enanthate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1123

Contraceptive efficacy of a depot progestin and androgen combination in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1123

Male hormonal contraception: effects of injections of testosterone undecanoate and depot medroxyprogesterone acetate at eight-week intervals in chinese men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1123

5alpha-reduction of norethisterone enhances its binding affinity for androgen receptors but diminishes its androgenic potency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1123

Low dose of cyproterone acetate and testosterone enanthate for contraception in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1123

Testosterone undecanoate maintains spermatogenic suppression induced by cyproterone acetate plus testosterone undecanoate in normal men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1123

Combined administration of a gonadotropin-releasing hormone antagonist and testosterone in men induces reversible azoospermia without loss of libido

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1123

Suppression of spermatogenesis to azoospermia by combined administration of GnRH antagonist and 19-nortestosterone cannot be maintained by this non-aromatizable androgen alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1123

Acyline: the first study in humans of a potent, new gonadotropin-releasing hormone antagonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1123

Suppression of a pituitary-ovarian axis by chronic oral administration of a novel nonpeptide gonadotropin-releasing hormone antagonist, TAK-013, in cynomolgus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1123

A sperm ion channel required for sperm motility and male fertility

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1123

Acidification of the male reproductive tract by a proton pumping (H+)-ATPase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1123

Twenty-One Day Administration of Dienogest Reversibly Suppresses Gonadotropins and Testosterone in Normal Men

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1123

Insertion and removal of Implanon

21 January 2018

1 reference

3 January 2024

https://opencitations.net/index/api/v1/citations/10.1016/S0010-7824(98)00121-8

The pharmacodynamics and efficacy of Implanon. An overview of the data

1 reference

12 January 2024

https://opencitations.net/index/api/v1/citations/10.1016/S0010-7824(98)00118-8

Identifiers

DOI

10.1517/13543784.13.9.1123

1 reference

10 August 2017

1 reference

PubMed ID

15330744